Portal de investigación
ESTUDIO DE FASE II, DE LA COMBINACION DE DOCETAXEL MAS CARBOPLATINO COMO QUIMIOTERAPIA PREOPERATORIA EN CANCER DE PULMON NO MICROCITICO
Datos básicos
- Protocolo:
- TAX-ESP-207
- EUDRACT:
- NO PROCEDE
- NCT:
- Centro:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.
Cordoba, Raul; (...); Martin Garcia-Sancho, Alejandro
Article. 10.1080/17474086.2024.2313457. 2024
A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).
Martínez-Banaclocha N; (...); Gumà J
Article. 10.3390/cancers16051034. 2024
A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
de la Fuente, Ana; (...); Ravassa, Susana
Article. 10.3390/cancers14122941. 2022
A Smart Digital Health Platform to Enable Monitoring of Quality of Life and Frailty in Older Patients with Cancer: A Mixed-Methods, Feasibility Study Protocol.
Papachristou, Nikolaos; (...); Bamidis, Panagiotis D.
Article. 10.1016/j.soncn.2023.151437. 2023
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).
Tavira B; (...); González-Martín A
Article. 10.1158/1078-0432.CCR-23-0771. 2024
Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
Martin, A. Gonzalez; (...); Selle, F.
Meeting Abstract. 10.1016/j.annonc.2023.10.031. 2023
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
Gonzalez-Martin, Antonio; (...); Selle, Frederic
Article. 10.1200/JCO.24.00668. 2024
Cancer worry at higher-risk sample of hereditary cancer in Spain.
Costa-Requena G, Richart-Aznar P, Segura-Huerta Á
Article. 10.1097/CEJ.0000000000000862. 2024
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L; (...); de la Cruz-Merino L
Article. 10.3389/fimmu.2024.1293931. 2024
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
Perez-Fidalgo, Jose Alejandro; (...); Gonzalez-Martin, Antonio
Article. 10.1136/ijgc-2022-004028. 2023
Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO.
Yubero-Esteban, Alfonso; (...); Sanchez Lorenzo, Maria Luisa
Meeting Abstract. 2022
Clinical insights from the rucaparib access program in Spain: A sub-analysis of long-term responders by GEICO.
Yubero-Esteban, Alfonso; (...); Gonzalez Martin, Antonio
Meeting Abstract. 2022
CNL and aCML should be considered as single entity based on molecular profiles and outcomes.
Carreño-Tarragona G; (...); Cross, Nicholas C. P.
Article. 10.1182/bloodadvances.2022008204. 2022
Comparison of psychological distress for breast, ovarian and colorectal cancer predisposition in a Spanish sample at high risk of hereditary cancer.
Costa-Requena, Gema; (...); Segura-Huerta, Angel
Article. 10.1097/CEJ.0000000000000734. 2022
Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2-metastatic breast cancer from the GEICAM/2013-02 PEARL study
Guerrero, Angel; (...); Martin, Miguel
Meeting Abstract. 2023
Characterization of the gene expression profile of breast cancer tumours in patients undergoing ovarian stimulation for fertility preservation purposes
Soriano, M. J.; (...); Diaz-Garcia, C.
Meeting Abstract. 2022
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Capdevila, J.; (...); Manzano, J. L.
Article. 10.1038/s41467-023-38611-5. 2023
Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).
Alejandro Perez-Fidalgo, Jose; (...); Gonzalez-Martin, Antonio
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.5549. 2021
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Rodríguez-Lescure Á; (...); de la Haba-Rodriguez J
Article. 10.1007/s12094-024-03411-w. 2024
Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/cancers15061705. 2023
Initial Clinical and Treatment Patterns of Advanced Differentiated Thyroid Cancer. ERUDIT Study.
Vallejo Casas, Juan Antonio; (...); Orcajo-Rincon, Lorenzo
Article. 10.1530/ETJ-21-0111. 2022
Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia
Alonso-Gordoa, T.; (...); de La Cruz, G.
Meeting Abstract. 2022
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis.
Palaz N-Carri N, Natalia; (...); de la Cruz-Merino, Luis
Article. 10.1158/1078-0432.CCR-22-0588. 2022
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Alamo IV registry.
Martin, Miguel; (...); Aguiar-Bujanda, David
Article. 10.1007/s10549-023-07002-1. 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Kristeleit, Rebecca; (...); Subbiah, Vivek
Article. 10.1007/s10637-023-01383-2. 2023
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.
Longo-Munoz, Federico; (...); Subbiah, Vivek
Article. 10.1016/j.ejca.2022.06.024. 2022
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.
Pena-Enriquez, Regina; (...); de la Haba-Rodriguez, Juan
Article. 10.1038/s41523-025-00718-x. 2025
MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Baste Rotllan, N.; (...); Mesia, R.
Meeting Abstract. 10.1016/j.annonc.2023.09.999. 2023
Multidisciplinary consensus on the criteria for fertility preservation in cancer patients.
Santaballa, A.; (...); Manau-Trullas, D.
Article. 10.1007/s12094-021-02699-2. 2022
Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
Fidalgo, JAP; (...); Gonzalez-Martin, A
Meeting Abstract. 10.1016/j.annonc.2021.08.1177. 2021
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
Perez-Fidalgo, JA; (...); Gonzalez-Martin, A
Article. 10.1016/j.esmoop.2021.100212. 2021
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03.
Garcia-Donas, Jesus; (...); Grande, Enrique
Article. 10.1007/s12094-023-03085-w. 2023
OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis-An exploratory joint analysis of the BRCA and non-BRCA cohorts.
Selle, Frederic; (...); Pujade-Lauraine, Eric
Meeting Abstract. 2022
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Martin, Miguel; (...); Gil-Gil, Miguel
Article. 10.1016/j.ejca.2022.03.006. 2022
Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.
del Olmo-Garcia, Maria I.; (...); Merino-Torres, Juan F.
Article. 10.3390/cancers14030584. 2022
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martin Garcia-Sancho, Alejandro; (...); Cordoba, Raul
Article. 10.1111/bjh.18941. 2023
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
García-Donas J; (...); Navarro P
Article. 10.1016/j.ygyno.2024.10.019. 2024
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
Ortuzar, Ariana; (...); Osorio, Santiago
Article. 10.1007/s00277-022-05044-x. 2022
Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial
Gustavo, Federico; (...); Albanell, Joan
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.1029. 2024
Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families
Fonfria, M; (...); Martinez-Duenas, E
Article. 10.3390/jpm11060548. 2021
Psychiatric symptoms in a Spanish sample with hereditary cancer risk.
Costa-Requena G; (...); Segura-Huerta Á
Article. 10.1007/s12687-022-00580-5. 2022
Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2-endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study
Tibau, A; (...); Albanell, J
Meeting Abstract. 10.1016/j.annonc.2021.03.108. 2021
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
Tibau, Ariadna; (...); Albanell, Joan
Article. 10.1177/17588359221148921. 2023
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell, J.; (...); Rojo, F.
Article. 10.1016/j.ejca.2021.11.010. 2022
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Harter P; (...); du Bois A
Article. 10.1056/NEJMoa2103294. 2021
Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study)
Redondo, Andres; (...); Gonzalez-Martin, Antonio
Article. 10.31083/j.ejgo4206163. 2021
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
Cueva, Juan F.; (...); Gonzalez-Martin, Antonio
Article. 10.1016/j.ejca.2022.12.023. 2022
Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial
Perez-Fidalgo, Jose Alejandro; (...); Gonzalez-Martin, Antonio
Meeting Abstract. 2024
Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program.
Yubero, Alfonso; (...); Gonzalez-Martin, Antonio
Case Reports. 10.1016/j.gore.2023.101211. 2023
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study
Yubero, Alfonso; (...); Gonzalez-Martin, Antonio
Article. 10.1186/s12885-022-10191-5. 2022
SEOM-GEICO clinical guidelines on endometrial cancer (2021).
Barretina-Ginesta MP; (...); Rubio-Pérez MJ
Article. 10.1007/s12094-022-02799-7. 2022
SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).
Castillón JC; (...); Plazas JG
Article. 10.1007/s12094-023-03205-6. 2023
SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022).
Guma, Josep; (...); Provencio, Mariano
Article. 10.1007/s12094-023-03206-5. 2023
Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/ijms23158526. 2022
The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Pizarro, David; (...); Palacios, Jose
Article. 10.3390/ijms241311183. 2023
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial
Albanell, Joan; (...); Rojo Todo, Federico Gustavo
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.1028. 2024